One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).~The drugs to be administered to patients are:~JAK-type kinase inhibitors.~Monoclonal antibodies against TNF.~Soluble receptor against TNF.~Biosimilar FAMEb.~Rituximab.~Abatacept.~Drugs that block IL6.~A follow-up will be carried out at 12, 24, 48, 60, 72 and 84 months from the start of treatment, to analyze how the patient's health improves.
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).~These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.